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-iAbstract
Cadherin and catenin-family proteins regulate adhesion in malignant melanoma.
Using AQUA (Automated Quantitative Analysis) to quantitate the levels of alphacatenin, beta-catenin, p120-catenin, N-cadherin, E-cadherin, and P-cadherin in melanoma
on tissue microarrays (TMA’s), we classified 513 patients by protein expression using
hierarchical clustering and regression analysis. The dendrogram supported positive
correlations seen upon Spearman rho analysis of P-cadherin and beta-catenin (r=0.5238,
p<0.0001) and negative, weak association of N-cadherin with other markers. Patients
with high expression of N-cadherin had the highest 20-year survival rate (p=0.0003).
Our adherens protein molecular classification of melanoma defines at least two
distinctive sub-populations of melanoma patients, those with high expression of Ncadherin and those with low expression who have decreased survival. These findings
extend previous cDNA array-based findings of an epithelioid class and neural crest class
of melanomas.
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-1Introduction
Melanoma is predicted to take the lives of approximately 7,910 patients in the
United States in 2006, according to the American Cancer Society’s age-adjusted
statistics. 62,190 people will be diagnosed with the deadly malignancy, 49,710 of those
will have melanoma in situ. According to the National Cancer Institute Surveillance,
Epidemiology and End Results (SEER) the incidence rate is increasing by 2.8% each year
(1981-2002), which is fortunately on the decline from a previously increasing rate of
6.1% (1981-2002) (1). The lifetime risk of developing melanoma for men is now
predicted to be 1 in 52 — and for women 1 in 77 (2).
Although melanoma can be a very serious cancer, the survival rates have been
increasing in recent years. The relative 5-year survival rate for all races between 19952001 was 92%, increased from 85% between 1983-1985, and 80% between 19741976(1,2). The death rates in white women have been decreasing since 1988, and for
men they have been on a decline since 1998. Although trends from the recent past are
showing encouraging new developments, melanoma is still the fifth most common cancer
in incidence for men and the sixth most common for woman in the United States (2).
Melanoma is the third leading cancer in Incidence Percent Change from 1992-2002 at
over 20% risk and over 40% burden for all ages (1).

Melanoma Staging Systems
Statistics show that melanoma proves itself as a deadly malignancy. To
determine treatment and prognosis, staging systems provide some ammunition in this
difficult fight. Physicians depend on these algorithms to determine how, when, and
where (locally or systemically) to treat. Besides guiding treatment, the evidence-based
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an accurate melanoma staging system, but the current standards have fallen short of our
expectations. When diagnosing malignant melanoma, physicians are forced to provide
wide-ranging survival estimates. Balch et al. showed that 10-year survival estimates in
stage II melanoma range from 50.8% ± 1.7 to 64.4% ± 2.2 and that stage III cancers
range from 18.4% ± 2.5 to 63.0% ± 4.4(3). Although predictive of survival, these broad
survival estimates are the basis for the most recent American Joint Commission of
Cancer (AJCC) staging system. The most recent changes were adopted in 2002, and the
current guidelines are based on tumor thickness, nodal involvement, and distant
metastasis. The requirements are shown below:
Table 1. TNM Classification of Melanoma (adapted from Kim et al. (4)).
Tumor (T) Classification Thickness (Breslow)
Presence of Ulceration
T1

< or = 1.0 mm

a: without ulceration
b: with ulceration or Clark level
IV or V

T2

1.01-2.0 mm

a: without ulceration
b: with ulceration

T3

2.0-4.0 mm

a: without ulceration
b: with ulceration

T4

>4.0 mm

a: without ulceration
b: with ulceration

Node (N) Classification

N1

Number of involved lymph

Level of lymph node

nodes

involvement

1 lymph node

a: micrometastasis
b: macrometastasis

-32-3 lymph nodes

N2

a: micrometastasis
b: macrometastasis

N3

Metastasis (M)

>4 metastatic lymph nodes,

a: micrometastasis

matted LN, or in-transit

b: macrometastasis

met(s)/satellite(s) and metastatic

c: in-transit met(s)/satellite(s)

lymph nodes

without metastatic lymph nodes

Site of Metastasis

Serum LDH Level

Distant skin, subcutaneous, or

Normal LDH

Classification
M1

lymph node metastases
M2

Lung metastases

Normal LDH

M3

All other visceral or distant

Normal LDH or elevated LDH

metastases

Table 2. AJCC Melanoma Stage Groupings (adapted from Kim et al. (4)).
Stage
T
N
M
0

Tis (in situ)

N0

M0

IA

T1a

N0

M0

IB

T1b

N0

M0

T2b

N0

M0

T3a

N0

M0

T3b

N0

M0

T4a

N0

M0

IIC

T4b

N0

M0

IIIA-C

Any T

N1 or N2 or N3

M0

IV

Any T

Any N

Any M1

T2a
IIA

IIB
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Sentinel Lymph Node Biopsy
Since melanoma staging depends on the number of involved lymph nodes, a
sentinel lymph node biopsy (SLNB) is a core requirement for complete diagnosis if the
tumor depth is greater than 1 mm. Messina et al. showed that immunohistochemistry
staining for S100 in the lymph nodes identified an additional 36% of detected metastatic
disease than just hematoxylin and eosin stain alone (5).
In 2006, Morton et al. tried to further strengthen the argument that the sentinel
lymph node biopsy improves survival. They showed that in 1269 patients the diseasefree survival rate was 78.3% for the SLNB group and only 73.1% for the observation
group (6). Although these numbers are significantly different, it is difficult to argue that
an increase survival of 5% is a monumental achievement. The study’s melanoma specific
death rate was nearly the same for both groups at 5 years (12.5% for SLNB patients and
13.8% for observation patients) suggesting that the effect of the SLNB may not be as
powerful as originally believed. Their results confirm that SLNB’s are useful to
accurately stage melanoma. However, the authors state that early SLNB can also
improve disease-free survival (6). This appears true based on their results, but when all
the results are carefully weighed, the slight improved survival is not reflected in the
melanoma death rate. For their hypothesis that SLNB improves survival to hold true, the
effects should be seen across all statistical methods of assessing improved survival.
Lymph node tissue has been the primary material/target for molecular
classification of melanoma to date. Researchers stain tissue for S-100 and HMB45, and
perform PCR analysis (7). The problem with new models of classification is the process
of obtaining lymph node tissue—a SLNB is required. Since melanoma is a deadly
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exposing the patient to new risks such as further surgical complications. Sentinel lymph
node biopsy is recommended for tumors >1.0 mm, but has had questionable merit in the
management of melanoma for tumors <1.0 mm. Ranieri suggests that melanomas >0.75
mm have a metastatic rate of 6.5%, and select patients with other risk factors such as high
mitotic activity should undergo SLNB (8). The procedure remains one of the crucial
components of our current American Joint Committee of Cancer (AJCC) melanoma
staging system (Tables 1 and 2) (9). Any nodal involvement elevates the cancer to stage
III. Prognosis estimates using the current system give wide-ranging survival estimates.
For example, patients with stage III cancers have survival rates ranging from 18.4% ± 2.5
to 63.0% ± 4.4 (3). These wide ranging estimates are not acceptable. Although few
effective adjuvant melanoma therapies exist, we should set out to find further methods to
refine the staging of melanoma.
One possible method for determining better survival estimates is the use of
molecular classification on primary and metastatic tissue. If clinicians are able to
molecularly classify primary tissue into different levels of disease, we could forgo the
need for invasive SLNB’s.

Molecular Classification of Melanoma
Advances in quantification technologies and analysis algorithms have allowed
molecular classification of melanoma on a number of small cohorts. By measuring
mRNA expression, Bittner et al. separated a cohort of melanoma patients into groups
characterized by motility and invasiveness. Although the model was not designed to
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melanoma patients might allow for better prognosis estimates or possibly more precise
treatment for subtypes of melanoma (10). Since these findings, two classes of uveal
melanoma have been defined based on gene expression: a “neural crest/melanocyte”
class and a more aggressive “epithelial” class. The epithelial class is noted to have
membranous staining of E-cadherin and beta-catenin and poor prognosis estimates (11).
Other studies have shown that an assortment of genes have variable expression on DNA
microarrays when comparing the changes that might occur as a melanocyte changes into
a malignant melanoma. The genetic transformations altered protein translation, which
was confirmed by measuring protein expression. They investigated genes and proteins
involved in: the NOTCH pathway, regulation of transcription, immune modulation,
membrane-trafficking, growth suppression as well as many other cellular processes (12).
In another study using comparative genomic hybridization, Bastian et al. classified thirty
cases of melanoma. They used fluorescence in situ hybridization to determine that
genomic amplification occurs well-outside the histologically demarcated tumor area in
acral melanomas. They demonstrated that genomic changes seen in invasive melanoma
are present in earlier stages of melanoma progression, by showing the same molecular
aberrations in melanoma in situ (13). Therefore, by classifying tumors molecularly, subtypes of melanoma can be distinguished even in the very beginning stages of
carcinogenesis.
Alonso and colleagues have completed the most significant study of this type
using tissue microarrays to molecularly classify melanoma. The examined expression of
thirty-nine markers on 165 cases of melanoma, evaluating cell cycle and apoptosis related
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validated with a different cohort and was found to be predictive independent of Breslow
depth of invasion (14). However, they did not use a quantitative form of
immunohistochemistry and used only seventy-two melanoma cases to validate their
predictor model. Our work will build on these findings by quantitating differences in
protein expression to classify a larger cohort of patients into prognostic groups.
Using immunohistochemistry on tissue microarrays to classify melanoma has
many advantages such as the ability to work easily with a large number of samples of
patient tissue, but the technique is limited by the quality and availability of effective
antibodies. During scientific exploration it is important to ask the right question, but
even more important than asking the correct question is the attainment and validation of
the supplies used to seek the correct answer.

Treatment of Metastatic Melanoma
The standard of care as a primary modality of treatment for malignant melanoma
is surgical resection of the tumor with boundaries of 2 mm for those with melanoma of >
4.0 mm in thickness (15,16). Many feel that SLNB is also part of the standard of care to
date (15,17). Patients with local recurrence or metastatic disease should receive adjuvant
therapy (15).
Most adjuvant therapies for stage IV metastatic melanoma patients are still in
investigational stages, and the few forms of therapy that have been used in practice are
not ideal. There is no clear treatment of choice because many of the adjuvant therapies
only help small percentages of patients in clinical trials; patients typically respond for
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cytotoxic treatments approved by the FDA to treat metastatic melanoma (18).
Hydroxyurea has not been used as commonly as dacarbazine. The former drug’s effects
on metastatic melanoma have been investigated for over thirty years, and although it is
the “standard of therapy” it only shows response rates of 15-25%. In less rigorous studies
small percentages of patients had been shown to survive up to 6 years, but these studies
are typically not reproducible (18). Various studies using dacarbazine alone or in other
regimens show median survival ranging from 4.6 to 11.9 months (19). Although the
survival time for patients with metastatic melanoma is only 6 to 9 months, minimal
improvement in survival comes at a price since all medications have side effects and
typical chemotherapeutics have very toxic side effects. A meta-analysis of recent “level
1” evidence studies have shown that dacarbazine as a single agent is as effective as
multiple-drug regimens (19). They point out that few quality of life studies have been
completed, but typical side effects of nausea, vomiting, fatigue, neutropenia,
thrombocytopenia, and anemia are considerably lower when taking dacarbazine as
monotherapy verses in a 4-drug Dartmouth regimen (dacarbazine, cisplatin, carmustine
and tamoxifen) (19).
All current forms of cytotoxic therapy typically show low response rates of less
than 25%. Researchers have been creative in searching out other treatments beyond
typical chemotherapeutics that may show efficacy. Scientists have tried tamoxifen,
thalidomide, interferon-alpha, and interleukin-2. The immunomodulators have response
rates ranging from 40-60%. Other treatments currently under early investigation in
mostly Phase 1 and 2 clinical trials include: sorafenib (a BRAF kinase inhibitor), human
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monoclonal antibodies (MEDI-522) (18).
A very recent Phase II study employing the use of dacarbazine as well as two
immunomodulators interleukin-2 and interferon-alpha, has shown one of the best
response rates and most promising survival effects to date. They measured the size of
metastatic tumors as well as disease-related symptoms to determine an overall response
rate of 52%. Median survival for partial responders was 27 months, while the few
patients who had a complete response with remission of symptoms and disappearance of
metastatic lesions for 4 weeks had an average survival of over 36 months. The median
survival of non-responders was 15 months. Although this is a very promising study, the
majority of patients had only a single site of metastasis in soft tissue or a lymph node
(20).
In conclusion, there is no clearly effective single adjuvant therapy regimen for
metastatic melanoma patients. Learning more about the biology and subtypes of
melanoma might allow us to develop more precise and effective therapies.

Cadherin and Catenins in Melanoma
Cancer metastasis is a crucial factor in determining patient prognosis. Cells must
detach from their surroundings, migrate to the blood stream, then grow and survive in a
new environment. Scientists are progressively learning which factors are important for
each step. For carcinoma cells to separate from neighboring cells, proteins that allow
adherence must be downregulated or destroyed (21). Voura et al. showed that during
flow through the bloodstream, melanoma cells will interact with endothelial cells via
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require the displaced tumor cells to “latch on” to cells in a new environment and then
continue to grow and divide. Our research will focus on the first stage of tumor
metastasis during which cells detach from their surroundings by altering amounts of
specific proteins that make up the adhesion complex.
The adhesion complex is composed of a variety of cadherins and catenins that
maintain the cell’s integrity with its environment. Cadherins are calcium-mediated,
adhesion glycoproteins that allow cell-to-cell interaction (Figure 1). Catenins,
cytoplasmic proteins, compose part of the adherens junction and are thought to be a part
of the signal that assures contact inhibition. The proteins secure the actin cytoskeleton to
the cell membrane. Cadherins and catenins interact to mediate cell adhesion. Ecadherin, as well as P-cadherin or N-cadherin, can bind directly to beta-catenin and p120catenin. Beta-catenin can then bind non-actin bound alpha-catenin. N-cadherin is
typically found in neural cell types, while E-cadherin is associated with epithelial tissue.
P-cadherin is typically found in embryonic tissue, but can be present elsewhere. Ecadherins bind to each other via homotypic interactions (23).

- 11 Figure 1. Cadherin and Catenin Biology. (© humpath.com adapted from
http://www.humpath.com/IMG/jpg/adherens_junctions-2.jpg).

Numerous malignancies including carcinoma of the esophagus, colon, stomach,
and breast have shown decreased levels of cadherin and catenin proteins when compared
to normal tissue particularly in more aggressive tumors (24-26).
Melanoma follows a similar pattern of loss of adherens junctional proteins when it
becomes more invasive. Decreased expression of E-cadherin in malignant melanoma
indicates worse disease-free survival for patients (27). Low expression of E- and Pcadherin seem to correlate with disease progression in melanoma (28). Unquantitated
immunohistochemical studies show a decrease in P-cadherin from primary to metastatic
melanoma, but no significant changes in E- or mesenchymal N-cadherin (29). Similar
studies show that maintaining P-cadherin expression is associated with better survival in
small tissue microarray cohorts (30). In reconstructed skin models P-cadherin exhibits
decreased metastatic invasion with retained expression independent of N-cadherin (31).
However, some studies with further refined methods of subcellular localization of marker
expression have found that E-cadherin, P-cadherin, and beta-catenin shift between the
nucleus, cytoplasm and membrane depending on tumor thickness and patient survival.
They used univariate and multivariate analysis to show that membranous N-cadherin
staining, cytoplasmic P-cadherin expression and loss of membranous E-cadherin
correlated with thicker and more aggressive tumors (32).
The catenins exhibit similar trends. Alpha-catenin expression is reciprocally
related to tumor thickness, suggesting that low alpha-catenin would correlate with a poor
prognosis (33). A decrease in expression of beta-catenin is seen comparing primary
melanoma to metastatic disease (29). A paucity of beta-catenin within carcinogenic

- 12 melanocytes is significantly associated with thicker tumors and decreased survival (32).
Very few studies have investigated the role that p120-catenin plays in melanoma, but one
study shows that p120 expression is correlated to beta-catenin expression in melanoma.
Other correlations to tumor thickness and comparisons between primary and metastatic
melanoma were not significant (33). Gamma-catenin often has little to no expression in
nevi or melanoma samples using immunohistochemistry (29,34). Despite this progress,
few studies show prognostic implications for immunohistochemical data and none show
quantitated expression of nearly all classic cadherin and catenin markers in a large cohort.
To further molecularly classify malignant melanoma, we investigated the
relationships among alpha-catenin, beta-catenin, p120-catenin, N-cadherin, E-cadherin,
and P-cadherin in melanoma tissue using quantifiable immunohistochemistry. Patient
subpopulations were created using hierarchical clustering based on protein expression
patterns, and then further assessed for survival to answer the most important question:
“Does molecular classification predict a patient’s length of survival?”

- 13 Hypothesis
In human melanoma tissue, does the expression pattern of six adhesion complex
proteins: α catenin, β catenin, p120-catenin, E-cadherin, N-cadherin, and P-cadherin
classify patients into distinctive sub-populations? Does molecular classification predict
survival?

Aims of Thesis
Aim 1:
First, we collected clinical information from a cohort of melanoma patients to use
in an analysis of protein expression from primary and metastatic melanoma tissue.
Second, we selected appropriate markers that have been previously implicated in
the progression of melanoma through a complete literature review. After validating the
selected six antibodies, we measured cadherin and catenin expression in primary and
metastatic melanoma tissue from the cohort of patients, melanoma cell lines, and nevi.
We used immunohistochemistry on tissue micro-arrays with an automated system to
analyze protein expression. By staining with anti S-100 antibody concurrently with each
marker antibody, we created a tumor mask for each sample to demarcate melanoma in
epithelial tissue. DAPI staining was used to distinguish nuclei from cytoplasm. The
overall score of protein staining was recorded.

Aim 2:
The relative levels of protein were linked and then analyzed with each patient’s
prognostic information (using Kaplan-Meier curves, COX analysis, and hierarchical

- 14 clustering) to detect whether molecular classification of melanoma could indicate
prognosis.
We hypothesize that there is a positive correlation between cadherin or catenin
expression and survival. The hope is possibly to relieve the need for a sentinel lymph
node biopsy. Technicians could perform immunohistochemical staining to detect the
aggressiveness of malignancy, and then determine the likelihood that the melanoma will
spread to other areas of the body. Therefore, patients might be spared the painful – and
not always predictive – procedure of sentinel lymph node biopsy. Additionally,
physicians will be able to better predict the aggressiveness of each specific case of
melanoma. As successful treatment modalities are identified, clinicians will be able to
more confidently guide patients to patient-specific treatment plans. Hopefully the
patients who need adjuvant therapy will be more readily identified.

- 15 Methods
Melanoma Tissue Microarrays (TMAs)
In order to systematically classify large cohorts of patients based on molecular
expression of proteins, scientists must have an effective and reproducible means of
performing these potentially large experiments. One such method employs the use of
tissue microarrays to decrease the amount of tissue used in each experiment as well as
ease the required work and time demands that traditional slides would demand. Figure 2
illustrates the steps to create a TMA.

Figure 2 (35). Tissue Microarray Construction. After a pathologist identifies the area
of interest, a core of sample tissue is drilled using a precision arraying instrument. The
cores are placed in a paraffin recipient block. Using a tape transfer system, 5-micrometer
thick sections are sliced from the block and cross-linked to slides. The final image shows
an example section of histospots on a slide. Each histospot is assigned a specific grid
location used to identify the spot after staining.
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which is of limited and coveted supply, and the reduction of slide-to-slide staining
variability that would be seen if comparing traditional slides. A downfall is that only a
small section of original tissue is represented on each slide, and a great percentage of the
tissue architecture is not represented. However, representative tissue is carefully selected
by pathologists when used in a TMA.
For our study, formalin-fixed, paraffin-embedded specimens from the archives of
the Yale University Department of Pathology were used to construct YTMA 59. YTMA
59 is a compilation of 512 melanoma specimens with nearly complete follow-up for
every case, including cause and date of death. All patients were diagnosed between 1959
and 1994. The array consists of primary (215), metastatic (283), and local recurrence
(14) specimens, along with nevi (22) and melanoma cell lines (mm127, mnt1, sk23,
mel888, mel624, melanocytes1, yugen8, yumac, yumor, yusac2, yusit1, 1241, 1335, 501,
928) as negative and positive controls, respectively. Descriptive characteristics of the
patients and melanoma samples from YTMA59 are summarized in Table 3.
Table 3. Descriptive statistics of patients with melanoma tissue on YTMA59.
N
Primary Melanoma Local Recurrence Metastatic Melanoma
Cohort

511

214

14

283

Age, mean (yrs)

469

57.8

57.6

53.3

Female

225

111

5

109

Male

272

102

9

161

Breslow, mean (mm)

260

2.47

5.20

3.03

Stage I-IIB

264

158

11

95

Stage III-IVA

89

30

1

58

- 17 To construct the TMA, we identified representative areas of melanoma, nevi, or
cell lines and placed 0.6 mm diameter cores into a recipient block using a precision
arraying instrument (Beecher Instruments, Silver Spring, MD). An ultraviolet, crosslinkable, tape transfer system (Instrumedics Inc., Hackensack, NJ) fastened 5-micrometer
sections to adhesive slides.
Each master block has each case represented by a single histospot. Every 10th
slide is stained with H&E and reviewed by a pathologist to confirm the diagnosis of
melanoma. An internal reviewer observed all histospots during staining. The slides were
enveloped with paraffin for storage. Each slide was cut as needed, but if storage was
required slides were placed in a nitrogen desiccation chamber to prevent antigen
oxidation. We have shown that these methods successfully store slides for up to 3
months (36).
Students working in the Rimm Laboratory prior to 2004 collected the patient data
for YTMA 59. I assisted with data collection for a new YTMA while working in 2004.

Fluorescent Immunohistochemical Staining
Fluorescent immunohistochemical staining utilizes immunologic interactions
between primary and secondary antibodies to link a fluorescent probe to a specific
protein target. Coons and colleagues were first to successfully link a fluorescent dye to
antibodies using the principles of immunohistochemistry (37). The general principles
and steps of immunohistochemistry are as follows: 1) antigen fixation: the tissue is
prepared (usually using formalin or paraformaldehyde) to preserve histological
architecture and cellular shape; 2) tissue sectioning: typically specimens are embedded in

- 18 paraffin wax or a whole mount can be prepared to give 3-dimensional cellular
information; 3) antigen retrieval: methods such as pressure-cooking slides in citrate
buffer or reagents like proteinase K, trypsin, or pepsin are used to disrupt the protein
cross-links from formalin fixation to unveil hidden epitopes; 4) blocking of background
staining: hydrogen peroxide will prevent non-immunologic staining; 5) direct or indirect
linkage of antibody to antigen and detection source: direct antibodies have a detection
source previously bound to the antibody, while indirect methods use a primary antibody
to bind to antigen, then a secondary antibody binds to primary antibody because it is
against the IgG of the specific animal in which the primary antibody was grown; indirect
linkage allows for detection amplification; the secondary antibody is typically conjugated
to biotin or horseradish peroxidase, and finally colorimetric agents such as DAB, or
linked fluorescent dyes such as cy5-tyramide, are added to allow for detection (38).
With the use of an epiflourescent microscope, we are able to locate molecular
targets. The natural tissue architecture is maintained because of in situ hybridization,
allowing us a more accurate assessment of molecular targets. We chose automated
quantitative immunohistochemistry because it even further standardizes the traditional
methodology of grading staining. Pathologists typically have relied on manually scoring
each slide as "0, 1+, 2+, 3+" in staining intensity. However, this traditional visual
assessment of each slide is time-consuming and subject to bias from individual raters.
Our laboratory has created a reliable system of automated quantitative
immunohistochemistry to forgo the downfalls of traditional manual staining techniques
(39).

- 19 Each TMA slide was first deparafinized using xylene, followed by one wash in
100% ethanol and then further diluted washes (95%, 90%, etc.) down to 50% ethanol and
50% water for three minutes at each dilution. The slides were transferred to deuterium
depleted (dd) water and boiled in a pressure-cooker in 6.5 mM Na-citrate buffer (pH 6.0)
for 15 minutes. Endogenous peroxidase activity was blocked using a solution of using
absolute methanol with 0.75% hydrogen peroxide for 30 minutes at room temperature.
The slides were washed with tris-buffered saline (TBS) twice, and then incubated with
0.3% bovine serum albumin (BSA)/1x TBS to diminish nonspecific background staining.
The following primary antibodies were used on separate slides at the following dilutions:
mouse anti-α-catenin (Zymed Laboratories, 180225, Clone CAT-7A4) 1:150, mouse antiβ-catenin (BD Transduction Laboratories, 610153, Clone 14) 1:2500, mouse anti-Ecadherin (BD Transduction Laboratories, 610181, Clone 36) 1:400, mouse anti-Pcadherin (BD Transduction Laboratories, 610227, Clone 56) 1:250, mouse anti-Ncadherin (Zymed Laboratories, 18-0224, Clone 3B9) 1:150, mouse anti-p120-catenin
(BD Transduction Laboratories, 610133, Clone 98) 1:400. The proper dilution for each
primary antibody was determined after staining melanoma test arrays at four different
dilutions based on values found in the literature. Envision goat anti-mouse-horseradish
peroxidase was used as a secondary antibody. All antibodies used in this study have been
previously validated and used by our laboratory (40-42). Subcellular localizations are all
consistent with previous descriptions for each antigen. Using 4', 6-diamidino-2phenylindole (DAPI) staining (1:100) we were able to differentiate each cell’s nucleus
from cytoplasm. S-100 was used to stain each case and define a region of interest (mask)
for the melanoma within each sample histospot at a dilution of 1:650 (DAKO) (43).
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nonspecific staining the additional protein marker was abandoned. Additionally, because
melanoma tissue rarely expresses gamma-catenin the possibility exists that staining may
have been accurate but not sufficient for our analysis.
I worked with a fellow medical student, Aaron J. Berger, to learn the
immunohistochemistry technique. For nearly half of the markers, we worked together on
the staining. I also assisted him in staining other potential markers at various
concentrations for his dissertation. Besides my own adhesion protein antibodies, I
performed the staining and titrations for the following markers while occasionally
utilizing Berger’s assistance: HIF-1alpha, ki67, p16, p21, p27, p53, cyclin D1, nm23.
Laboratory technicians, including Kyle DiVito, Melissa Cregger, Summar Siddiqui,,
occasionally mixed solutions for general staining purposes. I created my own dilutions of
antibodies.

Quantification
Histospot images were acquired using a modified computer-controlled
epifluorescence microscope (Olympus BX51 microscope with automated x, y, z stage
movement.) and an Olympus Motorized Reflected Fluorescence System and software (IP
lab v3.54, Scanalytics, Inc.), with an attached Cooke Sensicam QE High Performance
camera. The customized system automatically obtained images at the specified
wavelengths.
Dr. Robert Camp of our laboratory created a custom program that “finds” all
histospots and creates a system of identification utilizing the rows and columns. The
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the known grid system to identify the other tissue samples. The coordinates of all the
histospots are recorded to be used for linkage to clinical data (Figure 3).

Figure 3. Microarray image after spotfinder algorithm.

Tissue staining was graded on a scale from 0 to 4095 using the program AQUA
(Automated Quantitative Analysis), designed by Dr. Robert Camp. It allows for
computerized accession and quantification of tissue microarray protein levels. The Rapid
Exponential Subtracting Algorithm (RESA) produces a “non-nuclear mask” by
subtracting the DAPI (nuclei) image from the larger S100 (tumor mask) image for each
histospot. AQUA and RESA have been previously described by Camp et al. (Figure 4)
(39).
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Figure 4 (adapted from Aaron J. Berger 2006). AQUA software. The panels above
show the title pane, score window, settings window, algorithm window and four image
windows with raw and processed data from one example histospot. The upper left image
shows an original keratin immunofluorescence picture before the tumor mask is applied.
The upper right image window illustrates the tumor mask. The lower right pane
demonstrates the non-nuclear (cytoplasm) mask.

In brief, the computer and microscope system utilize two images, one taken at the
appropriate plane of focus and an additional image taken below the previous plane. The
second image is essentially just below the base of each 5-micron section of tissue. The
two high quality, monochromatic 0.5 micron resolution images allow for the distinction
of large subcellular compartments such as nuclei (39).
AQUA uses the following two algorithms, RESA and PLACE (pixel-based locale
assignment for compartmentalization of expression), to: 1) create each “tumor mask,” or
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quantify and locate biomarker florescence within tumor mask.
Using co-localization to measure the amount of target within the previously
defined “mask,” an AQUA score is determined for the entire tumor area, as well as for
the nucleic area and “non-nuclear” area (i.e. mostly cytoplasmic area). AQUA scores are
continuous variables and defined as (intensity of target)/area (Figure 5).

Figure 5 (adapted from Aaron J. Berger 2006). AQUA algorithm for melanoma.
The first column of images is raw, while the last column is post-AQUA melanoma
protocol. The first row of windows shows S100 protein expression (Alexa 488), a marker
specific for melanoma in epithelial tissue. The expression of S100 differentiates tumor
from surrounding tissue. The individually produced tumor mask is captured as a binary
image, and further refined by removing small objects and filling holes. Next AQUA
relies on the DAPI image to discriminate nuclei. Using RESA (Rapid Exponential
Subtracting Algorithm), the DAPI (nuclei) image is subtracted from the larger S100
(tumor mask) image to produce a non-nuclear (cytoplasm) mask. The final images in the
bottom horizontal row show RESA application to the target (HDM2) image. Cy5
immunofluorescence is used to capture specific marker staining. RESA uses exponential
subtraction to obtain the most precise quantification via pixel-based locale assignment for
compartmentalization of expression (PLACE algorithm). Following image acquisition,
the aforementioned masks are applied. The target localization image in the lower right
corner illustrates the final image used to quantitate the AQUA score, which is
intensity/area.
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Aaron Berger assisted me with the initial marker acquisitions, but after learning
the programs I set up and ran AQUA for my markers.

Statistical Analysis
Only histospots with tumor covering greater than 5% of tissue area were included
in our analysis. The specimens were linked to their respective prognostic information
using Cruella online. We used JMP 5.0.1, Statview 5.0.1 (SAS Institute Inc., Cary, NC),
and X-Tile software (http://www.tissuearray.org/rimmlab/xtile.html) for data analysis.
Survival curves were created using the Kaplan-Meier method (univariate analysis)(44).
The values of cadherin expression in the non-nuclear mask were used whenever these
markers could be analyzed separately to allow for more precise data interpretation. The
Cox proportional hazards test was used for univariate and multivariate analysis. Nonnormally distributed raw data was normalized using the natural log before individual
parametric tests. Otherwise, raw AQUA scores were always used during analysis.
Significant results required a p value of <0.05.

Non-Parametric Spearman Rho Scatterplot Matrix
A scatterplot matrix shows the magnitude of similarity or dissimilarity among
numerous markers. The matrix system allows for the comparison of each individual
marker to every other marker by first ranking the data, then calculating the scatterplot
matrix. The rho value denotes the degree of similarity, or “linear relationship,” and can
be positive or negative suggesting the type of association (direct or inverse) (45,46).
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X-Tile Software
To create the Kaplan-Meier survival curves, we used X-Tile software to find the
optimal binary cut-point in our data. We split our cohort into a training and validation
set. Each set contained half of our original cohort and was outcome matched. The
training set was used to define low- or high-expressing melanoma tissue for each specific
marker. We then tested the cut-point on the validation set to assess the prognostic value
of each marker (47).

Hierarchical Clustering
For hierarchical clustering, we first applied the natural log to tumor mask AQUA
scores to normalize raw data. Z-scores were produced from the normalized data and
values were analyzed with Cluster 2.11.0.0 and Gene TreeView 1.60
(http://rana.lbl.gov/EisenSoftware.htm). Using 80% present as the filter, 395 patients out
of 514 were included in the tree following average link clustering. Four minor clusters
equidistant from the patient cluster were arbitrarily chosen and analyzed with KaplanMeier survival curves.
Hierarchical clustering is a way to separate sub-groups of patients by similarity of
their expression profile. The idea is to cluster patients who are more similar to each other
than everyone else in the cohort by comparing each patient’s expression profile with all
other patient’s profiles. The analysis creates sub-populations by minimizing differences
within clusters and maximizing differences between different clusters. The process of
clustering produces a dendrogram of patient profiles and biomarkers. The branch length
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by selecting a point along the length of the patient dendrogram. Any point may be
chosen depending on how similar or dissimilar the groups are desired to be.
Additionally, the biomarkers also are placed in a dendrogram that suggests similarity or
dissimilarity of staining patterns. Patients, with their expression profiles, are placed in
order to create a “heat map.” The color and intensity (typically red denotes high
expression and green shows low expression) describes the quantity of protein in each
tissue sample. (48,49).
I performed all the statistical analysis with the occasional assistance from David
Rimm, M.D., Ph.D., Robert Camp, M.D., Ph.D., Annette Molinaro, Ph.D., Jena Giltmore,
and Melissa Cregger.

Results
Figure 6 illustrates the final image after RESA, PLACE, and AQUA algorithms
are applied to the images captured from the fluorescent stains. The marker in this image,
E-cadherin, demonstrates the mostly membranous staining of cadherins. Unfortunately
our image resolution does not allow for the distinction between membranous and
cytoplasmic staining.
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Figure 7. E-Cadherin immunofluorescence after AQUA algorithms of a single histospot.

Figure 7 demonstrates the image captured from S-100 staining, used to identify
the area of tumor. Notice normal stroma that is not stained surrounding melanoma tissue.
The photo is captured later translated into a binary image, not shown here.
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S-100

Figure 7. S-100 immunofluorescence of a single histospot.

Figure 8 shows the range and distribution of AQUA scores for alpha-catenin,
beta-catenin, p120-catenin, N-cadherin, E-cadherin and P-cadherin. N-cadherin
expression clearly was not expressed in a normal distribution; therefore, raw values were
normalized prior to analysis with parametric tests.

- 29 Figure 8. AQUA scores showing range and distribution for alpha-catenin, betacatenin, p120-catenin, N-cadherin, E cadherin and P-cadherin.

Table 4 shows the average AQUA values for each sub-group of histospots for all
analyzed markers.
Table 4. Average tumor mask staining of nevi, primary melanoma, local recurrence melanoma,
metastatic melanoma, and melanoma cell lines from YTMA59.
Alpha-catenin Beta-catenin P120-catenin E-cadherin N-cadherin P-cadherin
Nevi

156.512

901.949

358.414

534.688

248.896

641.745

Primary Melanoma

191.239

760.894

286.61

583.53

274.754

566.732

Local Recurrence

222.057

617.096

311.029

625.671

214.202

554.722

Metastatic Melanoma

218.386

703.36

322.897

488.782

197.335

544.113

Melanoma Cell Lines

320.399

1176.666

627.625

888.974

383.261

695.402

ANOVA p-value

<0.0001

<0.0001

<0.0001

0.0004

0.0003

<0.0001

Unpaired T-Tests
We found that mean alpha-catenin expression was the lowest in nevi (156.512)
and the highest in melanoma cell lines (320.399). Expression was increased in the
primary melanoma patient population (191.239) and significantly increased in the
metastatic group (218.386) when compared to regular nevi (p=0.0131). The local
recurrence population’s mean (222.057) was most similar to the metastatic’s mean. The
averages of primary and metastatic melanomas were significantly different (p=0.0055)
(Tables 4 and 5).
Beta-catenin also had the highest average expression in melanoma cell lines
(1176.66), but the tissue with the lowest expression was local recurrence melanoma
(617.096) followed by metastatic melanoma (703.36) and then primary melanoma
(760.894). The average nevi and primary tissues had a significant mean difference of
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beta-catenin (0.0128). Nevi and metastatic melanoma average scores were significantly
dissimilar with the largest difference seen in all the scores of 198.59 (p=0.0005).
P120-catenin expression was absolutely the highest in metastatic melanoma tissue
(627.625). Primary melanoma tissue showed the lowest average values with a mean of
286.61. Nevi showed average expression of p120-catenin that was much lower than
metastatic tissue, however higher than all other specimens (358.414). The only
interesting comparison of average values that was significant was the difference between
primary and metastatic tissue (p=0.0313).
E-cadherin followed the pattern of extremely high average expression within
melanoma cell lines (888.974). Metastatic tissue actually had the lowest mean expression
of 488.782. Only the difference between primary and metastatic tissue was significant
for E-cadherin (94.748, p=0.0055).
N-cadherin also had the highest mean expression within melanoma cell lines
(383.261). Metastatic melanoma was the lowest average expresser (197.335). The
difference between primary and metastatic tissue averages was significant (77.419,
p<0.0001).
Finally, P-cadherin likewise had the highest average AQUA score expressed in
melanoma cell lines (695.402). Metastatic melanoma expresses the lowest average score
of 544.113. A trend of decreasing average scores was seen from nevi to primary
melanoma, to local recurrence, to metastatic melanoma. All comparisons of nevi to
primary tissue, primary to metastatic, and nevi to metastatic were significant (75.013,
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seen with P-cadherin.
Table 5. Unpaired t-tests of all markers.
Alpha-catenin
Mean Difference T value

P Value

Nevi: Primary

-41.333

-1.407

0.1053

Primary: Metastatic

-29.267

-2.656

0.0055

Nevi: Metastatic

-70.6

-2.237

0.0131

Beta-catenin

Mean Difference T value

P Value

Nevi: Primary

141.056

2.173

0.031

Primary: Metastatic

57.534

2.499

0.0128

Nevi: Metastatic

198.59

3.51

0.0005

P120-catenin

Mean Difference T value

P Value

Nevi: Primary

71.804

1.71

0.0891

Primary: Metastatic

-36.287

-2.161

0.0313

Nevi: Metastatic

35.517

0.804

0.422

E-cadherin

Mean Difference T value

P Value

Nevi: Primary

-48.842

-0.528

0.5985

Primary: Metastatic

94.748

2.794

0.0055

Nevi: Metastatic

45.905

0.509

0.6111

N-cadherin

Mean Difference T value

P Value

Nevi: Primary

-25.858

-0.524

0.6011

Primary: Metastatic

77.419

3.978

<0.0001
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51.562

1.131

0.2588

P-cadherin

Mean Difference T value

P Value

Nevi: Primary

75.013

2.466

0.0145

Primary: Metastatic

22.619

2.163

0.0311

Nevi: Metastatic

97.632

3.689

0.0003

Non-Parametric Spearman Rho Scatterplot Matrix
Correlations of raw AQUA scores among all six protein markers are shown in
Figure 9. P-cadherin and beta-catenin express the highest rho value (r=0.5238,
p<0.0001). Beta-catenin shares a similarly strong correlation with E-cadherin (r=0.4494,
p<0.0001). E-cadherin correlates positively with alpha-catenin (r=0.3592, p<0.0001).
P120-catenin shares positive correlations with both alpha and beta-catenins (r=0.3480,
p<0.0001 and r=0.3638, p<0.0001, respectively).

- 33 -

Figure 9. Non-parametric Spearman rho scatterplot matrix depicting similarity in
staining intensity of measured cadherins and catenins. P-cadherin and beta-catenin
correlate with a rho of 0.5238 (p<0.0001). E-cadherin and beta-catenin increase at
proportional rates (rho=0.4494, p<0.0001). E-cadherin likewise corresponds with alphacatenin (rho=0.3592, p<0.0001). All associations are significant except N-cadherin when
paired with E-cadherin, P-cadherin and beta-catenin and the pairing of P-cadherin and
alpha-catenin.

However, N-cadherin shows an inverse correlation with all analyzed markers.
Besides being reciprocally related, the mesenchymal cadherin shows some of the weakest
correlations with other proteins. Although not significant, the correlations with betacatenin and E-cadherin are the lowest (r= -0.0451, p=0.8156 and r= -0.0573, p=0.1156,
respectively).
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created from analysis of our training cohort (50% of original cohort) with X-Tile, raw
AQUA scores of non-nuclear N- and E-cadherin significantly predicted patient survival
(Figure 10) (p=0.0222 and p=0.0233, respectively). The low expressing N-cadherin
(non-nuclear) group had a RR=1.883 (95% CI of 1.099-3.226, p=0.0212). The RR of Ecadherin (non-nuclear) for the low expression group was 1.532 (95% CI of 1.057-2.221,
p=0.0243). Univariate analyses of other markers are summarized in Table 5. E- and Ncadherin (non-nuclear) expression did not retain significance when analyzed with
Breslow, age, and gender.

Figure 10. Kaplan-Meier survival curves using cut-points created with X-tile for
non-nuclear expression of E-cadherin and N-cadherin. The validation cohort was
significant for N-cadherin (non-nuclear) when separating high and low expressing
melanomas at an AQUA score of 366 (p=0.0222). The E-cadherin (non nuclear)
validation set was significant between high and low expression groups using the X-tile
produced cut-point of 426 (p=0.0233).
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Table 5. Cox Proportional Hazards univariate and multivariate analysis of markers using X-tile
produced cut-points.
Univariate Analysis
Variable (Low expression)

N

Relative Risk 95% Confidence Interval

P Value

N-cadherin, non-nuclear

201

1.883

1.099-3.226

0.0212

E-cadherin, non-nuclear

164

1.532

1.057-2.221

0.0243

P-cadherin, non-nuclear

207

1.168

0.784-1.740

0.4447

Alpha-catenin

208

0.904

0.644-1.268

0.5578

Beta-catenin

210

1.386

0.908-2.114

0.1300

P120-catenin

186

1.224

0.860-1.740

0.2615

Multivariate Analysis

N

Relative Risk 95% Confidence Interval

P Value

1.094

0.999-1.198

0.0529

1.006

0.985-1.027

0.5886

Gender (female)

0.658

0.351-1.235

0.1928

N-cadherin, non-nuclear (low)

1.77

0.835-3.754

0.1365

Breslow depth (mm)
Age at diagnosis (yrs)
94

Multivariate Analysis

N

Relative Risk 95% Confidence Interval

P Value

1.109

1.012-1.215

0.0272

1.018

0.744-2.616

0.1429

Gender (female)

0.775

0.399-1.504

0.4505

E-cadherin, non-nuclear (low)

1.489

0.785-2.824

0.2223

Breslow depth (mm)
Age at diagnosis (yrs)
69

Hierarchical Clustering
Hierarchical clustering organized melanoma patients into four distinctive clusters
that individually shared similar expression profiles (Figure 11A). Only patients who had
sufficient protein expression with tumor covering greater than 5% area of the histospot in
at least five of six protein markers were included in average-linked clustering. Four
clusters were arbitrarily chosen at an equidistant point. Cluster 1 includes 167 patients
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of N-cadherin. These patients had the second highest survival rate of ~25% at 20 years
(Figure 11B). Cluster 2 has the lowest survival at 5 years (~27%) and the second lowest
at 20 years (~22%). The group includes 31 patients with generally low expression of
alpha-catenin and E-cadherin. Cluster 3 has relatively low or average expression of all
three cadherins and all three catenins. The survival of these 127 patients is the lowest of
the four clusters at 20 years (~12%). Cluster 4 expresses the highest relative levels of Ncadherin compared to other clusters. The 36 patients in cluster 4 had the highest survival
at 5 years (~68%) and 20 years (~50%). The survival curves were significant with
p=0.0003.
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Figure 11A. Hierarchical cluster and survival curve of melanoma patients based on
expression of indicated cadherins and catenins.
A. The hierarchical cluster produced by TreeView 1.60 and Cluster 2.11.0.0 (Eisen
Software, Berkeley, CA) includes 361 patients who had sufficient protein expression with
tumor covering greater than 5% area of the histospot in at least five of six protein
markers. Four clusters were arbitrarily chosen at an equidistant point. Red denotes high
expression, black is average, and green shows low expression. Cluster 1 (blue) shows
167 patients characterized by high expression of alpha-catenin and E-cadherin with
relatively low expression of N-cadherin. Cluster 2 (red) is composed of 31 patients who
had melanomas with generally low expression of alpha-catenin and E-cadherin. Cluster 3
(purple) is described by relatively low or average expression of all three cadherins and all
three catenins in a total of 127 patients. Cluster 4 (orange) has the highest relative levels
of N-cadherin compared to the other patients in the cohort. Other protein expression is
varied but generally decreased in the group of 36 patients.
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Figure 11B. Kaplan-Meier analysis of the four clusters with 20-year follow-up shows
significantly different survival rates (p=0.0003). Cluster 1 had a mean survival of 103.5
months, cluster 2 averaged 37.8 months, cluster 3 averaged 75.0 months, and cluster 4
had a mean of 85.1 months.

The adhesion protein dendrogram created from clustering is perhaps our most
interesting result. In accordance with the Kaplan-Meier survival curve and Spearman rho
scatterplot matrix, N-cadherin is the most dissimilar to other markers. P-cadherin and
beta-catenin share the most similarity.

Discussion
Patterns of Expression
The average expression of all three cadherins was the lowest in metastatic tissue.
The next lowest group of tissue was from local recurrence for N- and P-cadherin. Local
recurrence tissue is viewed by some as more similar to a metastasis than a primary tumor
because of its association with a higher death rate, and this molecular data may support
that classification (15).
Cell lines of melanoma showed the overwhelmingly highest averages of
expression for all markers (Table 4). Unfortunately, there was no corresponding pattern
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studies, our results may reflect the fact that cell lines of melanoma tissue have acquired
many mutations that deregulate normal cellular processes. These cells lines may have
lost a large number of traits that give them similarity to unmanipulated melanoma tissue.
In Table 5, t-tests show that primary tissue mean expression is statistically
different from metastatic melanoma tissue for every marker. This data further suggests
that adherens junctional protein regulation is altered as a tumor progresses from a
melanoma in situ to a more aggressive type, such as one that would cause metastatic
disease.

Biological Interactions of Cadherins and Catenins
Our results summarize previously know biological interactions among cadherins
and catenins. We have shown that P-cadherin and beta-catenin have extremely similar
expression profiles through Spearman rho correlations and a dendrogram after
hierarchical clustering. According to our data p120-catenin and alpha-catenin also share
similarity to the former proteins (Figure 11A). The high, positive rho values further
strengthen the argument, although alpha-catenin and P-cadherin are not significant in the
scatterplot matrix. Our findings reinforce the known binding of alpha-catenin to betacatenin because of their similar expression profiles and significant positive rho of 0.2280
(Figure 9). Likewise, alpha-catenin is linked to E-cadherin via a connecting protein,
beta-catenin (alpha-catenin to E-cadherin rho=0.3592, p<0.0001, and beta-catenin to Ecadherin rho=0.4494, p<0.0001) (50,51). When downregulation of any one linked
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follow suit.
Average-linked clustering produced a cluster tree highlighting the biological
interactions among the analyzed cadherins and catenins. N-cadherin separates early from
the other markers, suggesting that its expression is independent of the other proteins. The
two markers that are most closely linked to N-cadherin are E-cadherin and alpha-catenin.
Many researchers have highlighted the interaction between E and N-cadherin in
melanoma (29,52). Kuphal and Bosserhoff show that the loss of E-cadherin stimulates
the up-regulation of N-cadherin via induction of NFĸB.

Survival Analysis
We found that moderately high (or maintained) expression of N-cadherin and Ecadherin correlated with improved survival significantly. Our survival curves showing
low expression of E-cadherin in non-nuclear compartments confirms previous findings
that low E-cadherin is a marker of poor prognosis (27). High expression of alphacatenin, p120-catenin, and P-cadherin was associated with better survival, although not
significant (Table 5). This discovery was contrary to some findings described in the
literature, but these studies were mostly qualitative and often did not relate findings to
prognosis (29,33,34). We believe that if we could distinguish membranous staining from
cytoplasmic staining, we would see alpha-catenin expression only within the cytoplasm –
and not the membrane – in these metastatic cells. The potential decrease of catenin at
the adherens junction explains the increased mobility of metastatic cells.
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subpopulations of patients confirmed our hypothesis that patients with overall decreased
expression of adherens junctional proteins have decreased survival, possibly due to the
cancer’s ability to detach from its environment. This subtype of melanoma is consistent
with less differentiation and increased motility ability. Cluster 3, the subgroup with
generally low expression of all tested adhesion proteins, has the absolute lowest survival
rate from our cohort (Figure 11B).
The overall decrease in N-cadherin and beta-catenin expression in metastatic
melanoma suggests that adherens junctions deteriorate in cells that become metastatic.
Our findings support one of the requirements for metastatic melanoma; malignant cells
must be able to disassociate from neighboring cells to become metastatic.
We found that some of the select cadherins and catenins were up- and downregulated in a fashion that was not found to be independently significant. However, when
the six markers were analyzed in an algorithm that made use of all quantitated data, we
found that patients could be organized into distinct subgroups. These groups differed by
the amount and type of adhesion-complex protein expressed. When these groups were
plotted on a Kaplan-Meier curve, the prognosis of one population was significantly
different than other populations.
Just as the five proteins described above are similar in expression and allow us to
group patients into clusters with poor survival, strong expression of N-cadherin defines a
subpopulation of patients with the best survival of our cohort. Our findings are contrary
to previously reported epithelial-to-mesenchymal transition (EMT) studies. The EMT
describes the change in expression of adhesion proteins when a malignancy transforms
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via NFĸB signaling in melanoma. Downregulation of E-cadherin stimulates N-cadherin,
which is described as “cadherin switching” (53). However, the increase in N-cadherin is
shown in cell lines and has not been analyzed in regard to prognosis. Our data
summarizes a subpopulation of melanoma patients, and the EMT melanomas may be
describing a different class. Additionally, neural crest derived melanomas may be
entirely different from the epithelial carcinomas that have previously shown cadherin
switching. Cadherin switching may indicate more aggressive disease in epithelial derived
tumors, but in melanomas that are derived from the neural crest, retaining N-cadherin
may indicated a more highly differentiated tumor since the expression resembles a mature
melanocyte.
Limitations to our work include the problems encountered when dividing a cohort
into training and validation sets. Because we used a separate set of patients to determine
cut points for the validation set, we did not train the X-Tile tests on the same cohort of
patients. This should ensure the quality of our findings, however limiting the final
number of patients that could be included in analysis. Other limitations include the
inability to directly measure cytoplasmic, or even more specifically membranous,
expression of cadherins. While a more precise “membranous mask” would give our
experiments further accuracy, the catenin proteins were properly measured in the entirety
of the tumor. Catenins can be found in the cytoplasm and nucleus, as well as attached to
E-cadherin complexes or individually placed within the cell (50). Although we attempted
to include gamma-catenin in our studies, heterogeneous staining presumably due to a
nonspecific antibody prevented us from presenting a more complete picture of the
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low levels in melanoma, and our staining methods did not allow for accurate assessment.
In summary, the expression profile of tumors reflects known biological
interactions of cadherins and catenins. Our scatterplot matrix and biomarker dendrogram
exemplified the relationships. Molecular classification using AQUA technology may
identify less aggressive sub-types of melanoma.
We identified at least two subclasses of melanoma that correlate with survival: 1)
one with strong expression of N-cadherin, which identifies patients with the best survival
of our cohort; and 2) a second subclass with a very poor outcome that includes two
distinctive molecular classes: A) one with downregulation of essentially all the cadherincatenin complex proteins as would be seen in a poorly differentiated tumor; and B)
another that includes patients with high levels of all the cadherin-catenin proteins
consistent with an epithelioid type of melanoma.
More recent work in our laboratory has shown that after stratifying the cohort into
primary and metastatic disease, our results hold true when analyzing simply primary
tissue. These results would allow for even earlier identification of aggressive subtypes of
melanoma, therefore, possibly alleviating the need of a SLNB. Clinicians would be able
to recognize patients with more aggressive forms of melanoma even before metastasis
occurs, allowing quicker and possibly more targeted forms of therapy. Immediate
practical application of this work includes the ability to classify patients into clearer and
more precise sub-groups based on the aggressiveness of disease. This will allow
clinicians to determine which patients may benefit from certain therapeutics, when
successful adjuvant therapies are identified.
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study expands on their work by showing that molecular classification of melanoma
correlates with survival and can indicate prognosis. Our bench-work science clearly can
be applied to the bedside, and may benefit melanoma patients in the near future.
Future studies in this area could use larger cohorts of purely primary tissue to
further strengthen the power of the analysis. Once a validated antibody of gammacatenin can effectively stain melanoma tissue, more complete analysis of the cadherin
and catenin family can occur. Other markers such as phosphorylated beta-catenin and
cadherin 11 can be explored as well. We had difficulty obtaining precise and accurate
staining with these antibodies. Additionally, further refinements in technique will allow
for quantification of biomarkers within more precise areas of the cell, such as purely
cytoplasmic, membranous, or nuclear-membranous staining. Further statistical
exploration with a larger cohort might produce a predictor model that can be used in
clinical practice. Later studies could use aggressive-disease melanoma tissue identified
through the predictor model to test the efficacy of treatment modalities. Adjuvant
therapy is only used in late stages of melanoma, but early treatment to this subgroup of
patients might prove to be more effective. Furthermore, treating specific subgroups of
melanoma patients might reveal a higher response rate and greater effect on survival if
we are able to identify subtype-specific treatments, like the advancements seen in
estrogen receptor positive breast malignancies.

- 45 References
(1) Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al.
SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD.
2004; Available at: http://seer.cancer.gov/csr/1975_2002/. Accessed 12/21, 2005.
(2) American Cancer Society. Facts and Figures. 2006.
(3) Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al.
Final version of the American Joint Committee on Cancer staging system for cutaneous
melanoma. J.Clin.Oncol. 2001 Aug 15;19(16):3635-3648.
(4) Kim K, Pang KM, Evans M, Hay ED. Overexpression of beta-catenin induces
apoptosis independent of its transactivation function with LEF-1 or the involvement of
major G1 cell cycle regulators. Mol.Biol.Cell 2000 Oct;11(10):3509-3523.
(5) Messina JL, Glass LF, Cruse CW, Berman C, Ku NK, Reintgen DS.
Pathologic examination of the sentinel lymph node in malignant melanoma.
Am.J.Surg.Pathol. 1999 Jun;23(6):686-690.
(6) Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et
al. Sentinel-node biopsy or nodal observation in melanoma. N.Engl.J.Med. 2006 Sep
28;355(13):1307-1317.
(7) Ribuffo D, Gradilone A, Vonella M, Chiummariello S, Cigna E, Haliassos N,
et al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative
sentinel nodes in malignant melanoma. Ann.Surg.Oncol. 2003 May;10(4):396-402.
(8) Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman JJ,3rd. The
prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann.Surg.Oncol.
2006 Jul;13(7):927-932.
(9) Kim CJ, Reintgen DS, Balch CM, AJCC Melanoma Staging Committee. The
new melanoma staging system. Cancer Control 2002 Jan-Feb;9(1):9-15.
(10) Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular
classification of cutaneous malignant melanoma by gene expression profiling. Nature
2000 Aug 3;406(6795):536-540.
(11) Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW.
Functional gene expression analysis uncovers phenotypic switch in aggressive uveal
melanomas. Cancer Res. 2006 May 1;66(9):4602-4609.
(12) Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al.
Expression profiling reveals novel pathways in the transformation of melanocytes to
melanomas. Cancer Res. 2004 Aug 1;64(15):5270-5282.

- 46 (13) Bastian BC, Kashani-Sabet M, Hamm H, Godfrey T, Moore DH,2nd,
Brocker EB, et al. Gene amplifications characterize acral melanoma and permit the
detection of occult tumor cells in the surrounding skin. Cancer Res. 2000 Apr
1;60(7):1968-1973.
(14) Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, et al.
Progression in cutaneous malignant melanoma is associated with distinct expression
profiles: a tissue microarray-based study. Am.J.Pathol. 2004 Jan;164(1):193-203.
(15) Reintgen D. Establishing a standard of care for the patient with melanoma.
Ann.Surg.Oncol. 2001 Mar;8(2):91.
(16) Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, et al.
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision
margins for 740 patients with 1-4 mm melanomas. Ann.Surg.Oncol. 2001 Mar;8(2):101108.
(17) Otley CC. Sentinel lymph node biopsy for melanoma--standard of care?
Dermatol.Surg. 2000 Nov;26(11):1067-1069.
(18) Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic
melanoma: time for a change? Cancer 2007 Jan 2.
(19) Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in
metastatic melanoma: what have we learned in 30 years? Eur.J.Cancer 2004
Aug;40(12):1825-1836.
(20) Neri B, Vannozzi L, Fulignati C, Pantaleo P, Pantalone D, Paoletti C, et al.
Long-term survival in metastatic melanoma patients treated with sequential
biochemotherapy: report of a Phase II study. Cancer Invest. 2006 Aug-Sep;24(5):474478.
(21) Birchmeier W, Weidner KM, Hulsken J, Behrens J. Molecular mechanisms
leading to cell junction (cadherin) deficiency in invasive carcinomas. Semin.Cancer Biol.
1993 Aug;4(4):231-239.
(22) Voura EB, Sandig M, Kalnins VI, Siu C. Cell shape changes and
cytoskeleton reorganization during transendothelial migration of human melanoma cells.
Cell Tissue Res. 1998 Sep;293(3):375-387.
(23) Huber O, Bierkamp C, Kemler R. Cadherins and catenins in development.
Curr.Opin.Cell Biol. 1996 Oct;8(5):685-691.
(24) Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S, et al.
Beta-catenin expression in human cancers. Am.J.Pathol. 1996 Jan;148(1):39-46.

- 47 (25) Shiozaki H, Iihara K, Oka H, Kadowaki T, Matsui S, Gofuku J, et al.
Immunohistochemical detection of alpha-catenin expression in human cancers.
Am.J.Pathol. 1994 Apr;144(4):667-674.
(26) Hashizume R, Koizumi H, Ihara A, Ohta T, Uchikoshi T. Expression of betacatenin in normal breast tissue and breast carcinoma: a comparative study with epithelial
cadherin and alpha-catenin. Histopathology 1996 Aug;29(2):139-146.
(27) Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo
GM. Expression of S100A4 combined with reduced E-cadherin expression predicts
patient outcome in malignant melanoma. Mod.Pathol. 2004 Aug;17(8):990-997.
(28) Seline PC, Norris DA, Horikawa T, Fujita M, Middleton MH, Morelli JG.
Expression of E and P-cadherin by melanoma cells decreases in progressive melanomas
and following ultraviolet radiation. J.Invest.Dermatol. 1996 Jun;106(6):1320-1324.
(29) Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J.
Alterations in cadherin and catenin expression during the biological progression of
melanocytic tumours. Mol.Pathol. 1999 Jun;52(3):151-157.
(30) Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD.
Identification of P-cadherin in primary melanoma using a tissue microarrayer: prognostic
implications in a patient cohort with long-term follow up. Ann.Plast.Surg. 2005
Sep;55(3):316-320.
(31) Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander
Haeghen Y, et al. P-cadherin promotes cell-cell adhesion and counteracts invasion in
human melanoma. Cancer Res. 2005 Oct 1;65(19):8774-8783.
(32) Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA.
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of
melanocytic tumors and prognosis in cutaneous melanoma. Clin.Cancer Res. 2005 Dec
15;11(24 Pt 1):8606-8614.
(33) Zhang XD, Hersey P. Expression of catenins and p120cas in melanocytic
nevi and cutaneous melanoma: deficient alpha-catenin expression is associated with
melanoma progression. Pathology 1999 Aug;31(3):239-246.
(34) Krengel S, Groteluschen F, Bartsch S, Tronnier M. Cadherin expression
pattern in melanocytic tumors more likely depends on the melanocyte environment than
on tumor cell progression. J.Cutan.Pathol. 2004 Jan;31(1):1-7.
(35) DeVita VT, Hellman S, Rosenberg SA. Cancer, principles & practice of
oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 2898-2898.
(36) DiVito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of
antigenicity on tissue microarrays. Lab.Invest. 2004 Aug;84(8):1071-1078.

- 48 (37) Coons AH, Creech HJ, Jones RN. Immunological propterties of an antibody
containing a fluorescent group. Proc. Soc. Exp. Biol. Med. 1941;Vol. 47:200--202.
(38) Cattoretti G, Ellis R, Kiernan J, Miller R, Peters S, Richmond R, et al.
Immunohistochemistry World: Introduction to Immunohistochemistry. 2005; Available
at: http://www.ihcworld.com/introduction.htm#intro. Accessed 1/12, 2007.
(39) Camp RL, Chung GG, Rimm DL. Automated subcellular localization and
quantification of protein expression in tissue microarrays. Nat.Med. 2002
Nov;8(11):1323-1327.
(40) Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL.
Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased
expression is associated with poor outcome. Cancer Res. 2006 May 15;66(10):54875494.
(41) Dillon DA, D'Aquila T, Reynolds AB, Fearon ER, Rimm DL. The
expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin
and E-cadherin. Am.J.Pathol. 1998 Jan;152(1):75-82.
(42) Reyes-Mugica M, Meyerhardt JA, Rzasa J, Rimm DL, Johnson KR,
Wheelock MJ, et al. Truncated DCC reduces N-cadherin/catenin expression and calciumdependent cell adhesion in neuroblastoma cells. Lab.Invest. 2001 Feb;81(2):201-210.
(43) Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T.
Immunohistochemical study of melanocytic nevus and malignant melanoma with
monoclonal antibodies against S-100 subunits. Cancer 1990 Aug 15;66(4):765-771.
(44) Gordis L. Epidemiology. 2nd ed. Philadelphia: W.B. Saunders; 2000.
(45) Environmental Systems Research Institute, Inc. Scatterplot. 2002; Available
at:
http://edndoc.esri.com/arcobjects/8.3/Samples/Analysis%20and%20Visualization/Scatter
plot/Scatterplot.htm. Accessed 1/12, 2007.
(46) Lane DM. HyperStat Online Statistics Textbook: Spearman's rho. 2006;
Available at: http://davidmlane.com/hyperstat/A62436.html. Accessed 1/12, 2007.
(47) Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool
for biomarker assessment and outcome-based cut-point optimization. Clin.Cancer Res.
2004 Nov 1;10(21):7252-7259.
(48) Chipman H, Tibshirani R. Hybrid hierarchical clustering with applications to
microarray data. Biostatistics 2006 Apr;7(2):286-301.
(49) Guess MJ, Wilson SB. Introduction to hierarchical clustering.
J.Clin.Neurophysiol. 2002 Apr;19(2):144-151.

- 49 (50) Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin
complex formation: novel protein interactions and pathways of complex assembly. J.Cell
Biol. 1994 Jun;125(6):1327-1340.
(51) Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to
the membrane adhesion complex. Proc.Natl.Acad.Sci.U.S.A. 1995 Sep 12;92(19):88138817.
(52) Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of Ecadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene
2004 Nov 4;23(52):8509-8519.
(53) Kuphal S, Bosserhoff AK. Influence of the cytoplasmic domain of Ecadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene 2006
Jan 12;25(2):248-259.

